2Gralow JR, Burstein HI, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease [ J ]. J Clin Oncol, 2008,26 ( 5 ) : 814- 819.
3Rajah R, Esteva FJ, Symmans WF. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response [ J ]. Clin Breast Cancer, 2004,5 ( 3 ) : 235-238.
4Sassen S, Fend F, Avril N. Histopathologic and metabolic criteria for assessment of treatment response in breast cancer [ J ]. PET Clin, 2005,1 ( 1 ) : 83-94.
5Adams AL, Eltoum I, Krontiras H, et al. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma [ J ]. Breast J, 2008,14 (2) : 141-146.
6Moreno A, Escobedo A, Benito E, et al. Pathologic changes related to CMF primary chemotherapy in breast cancer [ J]. Breast Cancer Res Treat, 2002, 75(2) : 119-125.
7Fisher ER,Wang J,Bryant J,et al.Pathobiology of preoperative chemotherapy:findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18.Cancer,2002,95:681-695.
9Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Ontology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2testing in breast cancer.J Clin Oncol,2007,25:118-145.
10Taucher S,Rudas M,Gnant M,et al.Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.Endoer Relat Cancer,2003,10:91-98.
